<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063034</url>
  </required_header>
  <id_info>
    <org_study_id>CSD1602</org_study_id>
    <nct_id>NCT03063034</nct_id>
  </id_info>
  <brief_title>CSD1602: A Crossover Study to Evaluate the Exposure to &quot;Tar&quot; and Nicotine From Two King Size Menthol Cigarette Products</brief_title>
  <official_title>CSD1602: A Crossover Study to Evaluate the Exposure to &quot;Tar&quot; and Nicotine From Two King Size Menthol Cigarette Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Davita Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate exposure to &quot;tar&quot; and nicotine from two menthol cigarette products&#xD;
      and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette&#xD;
      products. Mouth-level exposure is the measurement of substance trapped in the cigarette butt&#xD;
      after smoking the cigarette.&#xD;
&#xD;
      Other purposes of this study are to:&#xD;
&#xD;
        -  Compare the plasma cotinine, a byproduct of your body's processing of nicotine, levels&#xD;
           found in users after smoking each of two different cigarettes.&#xD;
&#xD;
        -  Find out the daily mouth-level exposure to cigarette &quot;tar&quot; and nicotine from smoking&#xD;
           each of two different cigarettes in adult smokers.&#xD;
&#xD;
        -  Determine if certain measures of nicotine dependence change based on the type of&#xD;
           cigarette smoked&#xD;
&#xD;
        -  To compare product liking and intent to use it again.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of one group of approximately 40 adult subjects randomly assigned to&#xD;
      the order in which they will smoke two study menthol cigarette products (including one&#xD;
      comparator product and one test product). Subjects will smoke each study product exclusively&#xD;
      for approximately one week prior to a test visit, with a different product smoked each week&#xD;
      over a two-week period. Cigarette butts will be collected the day prior to each test visit&#xD;
      for determination of MLE &quot;tar&quot; and nicotine levels. Blood samples will be collected at each&#xD;
      test visit for determination of plasma cotinine levels. Subjects will provide responses to&#xD;
      questions during each test visit to assess their cigarette smoking and cigarette butt&#xD;
      collection behavior during the preceding day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">March 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mouth-level exposure (MLE) &quot;tar&quot; per cigarette and MLE nicotine per cigarette.</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the per cigarette MLE parameters (MLE &quot;tar&quot; per cigarette and MLE nicotine per cigarette) from smoking PD21864AA with those from smoking PD21864AB in adult smokers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>PD21864AA, PD21864AB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD21864AB, PD21864AA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PD21864AA</intervention_name>
    <description>A king size menthol cigarette.</description>
    <arm_group_label>PD21864AA, PD21864AB</arm_group_label>
    <arm_group_label>PD21864AB, PD21864AA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PD21864AB</intervention_name>
    <description>A king size menthol cigarette.</description>
    <arm_group_label>PD21864AA, PD21864AB</arm_group_label>
    <arm_group_label>PD21864AB, PD21864AA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read, understand, and willing to sign an Informed Consent Form (ICF).&#xD;
&#xD;
          -  Generally healthy males and females, 21 years of age or older, at Screening-Enrollment&#xD;
             Visit.&#xD;
&#xD;
          -  Self-reports smoking at least seven cigarettes per day and inhaling the smoke.&#xD;
&#xD;
          -  Usual brand of cigarette is one of the brand styles specified.&#xD;
&#xD;
          -  Smoked usual brand for ≥ 3 months.&#xD;
&#xD;
          -  Agrees to exclusively smoke the study cigarettes and not smoke or use any other&#xD;
             tobacco or nicotine-containing products during the course of the study.&#xD;
&#xD;
          -  Able to read and comprehend English.&#xD;
&#xD;
          -  Able to safely perform the required study procedures, as determined by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Self-reported history of heart disease, kidney disease, asthma or any other lung&#xD;
             disease, diabetes, liver disease, hypertension, or hypercholesterolemia.&#xD;
&#xD;
          -  At risk for heart disease, i.e., obesity (body mass index [BMI] ≥ 40 kg/m2), as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          -  Females ≥ 35 years of age currently using systemic, estrogen-containing contraception,&#xD;
             or hormone replacement therapy.&#xD;
&#xD;
          -  Postponing a decision to quit smoking (defined as planning a quit attempt within 30&#xD;
             days of the Screening-Enrollment Visit) to participate in this study.&#xD;
&#xD;
          -  Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge,&#xD;
             patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract&#xD;
             within 30 days prior to the Screening-Enrollment Visit.&#xD;
&#xD;
          -  Females who test positive for pregnancy, are pregnant or breastfeeding, or plan to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
          -  Determined by the Investigator to be inappropriate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Yoon, FNP-C</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>St Charles FK, Kabbani AA, Borgerding MF. Estimating tar and nicotine exposure: human smoking versus machine generated smoke yields. Regul Toxicol Pharmacol. 2010 Feb;56(1):100-10. doi: 10.1016/j.yrtph.2009.08.011. Epub 2009 Aug 31.</citation>
    <PMID>19723554</PMID>
  </reference>
  <reference>
    <citation>Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012 Jan;14(1):75-8. doi: 10.1093/ntr/ntr137. Epub 2011 Oct 24.</citation>
    <PMID>22025545</PMID>
  </reference>
  <reference>
    <citation>Shepperd CJ, St Charles FK St, Lien M, Dixon M . Validation of methods for determining consumer smoked cigarette yields from cigarette filter analysis. Beitr Tabakforsch Int. 2006;22:176-184.</citation>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

